Neuphoria Therapeutics, Inc. (NEUP)
3.08
-0.28
(-8.33%)
USD |
NASDAQ |
Oct 29, 16:00
3.08
0.00 (0.00%)
After-Hours: 20:00
Neuphoria Therapeutics PE Ratio
PE Ratio Chart
Historical PE Ratio Data
| Date | Value |
|---|---|
| June 29, 2026 | 3.458 |
| June 26, 2026 | 3.591 |
| June 25, 2026 | 3.418 |
| June 24, 2026 | 3.528 |
| June 23, 2026 | 3.426 |
| June 22, 2026 | 3.489 |
| June 18, 2026 | 3.387 |
| June 17, 2026 | 3.387 |
| June 16, 2026 | 3.364 |
| June 15, 2026 | 3.371 |
| June 12, 2026 | 3.434 |
| June 11, 2026 | 3.528 |
| June 10, 2026 | 3.474 |
| June 09, 2026 | 3.662 |
| June 08, 2026 | 3.670 |
| June 05, 2026 | 3.528 |
| June 04, 2026 | 3.804 |
| June 03, 2026 | 3.694 |
| June 02, 2026 | 3.843 |
| June 01, 2026 | 4.165 |
| May 29, 2026 | 4.173 |
| May 28, 2026 | 4.212 |
| May 27, 2026 | 4.244 |
| May 26, 2026 | 4.292 |
| May 22, 2026 | 4.306 |
| Date | Value |
|---|---|
| May 21, 2026 | 4.024 |
| May 20, 2026 | 3.874 |
| May 19, 2026 | 3.748 |
| May 18, 2026 | 3.709 |
| May 15, 2026 | 3.717 |
| May 14, 2026 | 4.00 |
| May 13, 2026 | 3.914 |
| May 12, 2026 | 3.874 |
| May 11, 2026 | 4.063 |
| May 08, 2026 | 4.173 |
| May 07, 2026 | 4.196 |
| May 06, 2026 | 4.228 |
| May 05, 2026 | 4.240 |
| May 04, 2026 | 4.157 |
| May 01, 2026 | 4.102 |
| April 30, 2026 | 4.142 |
| April 29, 2026 | 4.079 |
| April 28, 2026 | 4.024 |
| April 27, 2026 | 4.047 |
| April 24, 2026 | 3.961 |
| April 23, 2026 | 3.858 |
| April 22, 2026 | 3.874 |
| April 21, 2026 | 3.827 |
| April 20, 2026 | 3.953 |
| April 17, 2026 | 3.748 |
PE Ratio Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| Agenus, Inc. | 2.673 |
| Amgen, Inc. | 28.62 |
| Anika Therapeutics, Inc. | -- |
| BioCryst Pharmaceuticals, Inc. | -- |
| Imunon, Inc. | -- |
PE Ratio Related Metrics
| PS Ratio | 11.54 |
| Price to Book Value | 0.6775 |
| Price | 3.08 |
| Earnings Yield | -200.8% |
| Market Cap | 16.67M |